BIO-TECHNE Corp OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
BIO-TECHNE Corp (TECH) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of -$3.61 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-10.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2016-05-10
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2016-03-31 was -$3.61M, a 319.65% decline year-over-year.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-12-31 was $3.47M, a 558.94% increase year-over-year.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-09-30 was -$3.75K.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-06-30 was $1.82M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2015 was $3.90M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2014 was -$17.11M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2013 was -$2.13M, a 109.09% decline from fiscal 2012.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2012 was $23.42M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|---|---|
| 2016-03-31 | -$3.61M 10-Q · filed 2016-05-10 | -$145.00K derived: sum of 2 quarters · filed 2016-05-10 | -$3.92M 10-Q · filed 2016-05-10 | $1.68M derived: sum of 4 quarters · filed 2016-05-10 | |
| 2015-12-31 | $3.47M 10-Q · filed 2016-02-09 | -$306.00K 10-Q · filed 2016-02-09 | $5.29M derived: sum of 3 quarters · filed 2016-02-09 | $6.93M derived: sum of 4 quarters · filed 2016-05-10 | |
| 2015-09-30 | -$3.75K 10-Q · filed 2015-11-09 | $1.82M derived: sum of 2 quarters · filed 2015-11-09 | $3.47M derived: sum of 3 quarters · filed 2016-05-10 | $3.99M derived: sum of 4 quarters · filed 2016-05-10 | |
| 2015-06-30 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $3.47M derived: sum of 2 quarters · filed 2016-05-10 | $4.00M derived: sum of 3 quarters · filed 2016-05-10 | $3.90M 10-K · filed 2015-08-31 | |
| 2015-03-31 | $1.64M 10-Q · filed 2016-05-10 | $2.17M derived: sum of 2 quarters · filed 2016-05-10 | $2.07M 10-Q · filed 2016-05-10 | $1.95M derived: sum of 4 quarters · filed 2016-05-10 | |
| 2014-12-31 | $526.00K 10-Q · filed 2016-02-09 | $426.00K 10-Q · filed 2016-02-09 | $302.90K derived: sum of 3 quarters · filed 2016-02-09 | $344.90K derived: sum of 4 quarters · filed 2016-02-09 | |
| 2014-09-30 | -$100.00 10-Q · filed 2015-11-09 | -$100.00K 10-Q · filed 2014-11-10 | -$223.10K derived: sum of 2 quarters · filed 2015-11-09 | -$181.10K derived: sum of 3 quarters · filed 2015-11-09 | $285.90K derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-06-30 | -$223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | -$181.00K derived: sum of 2 quarters · filed 2015-08-31 | $286.00K derived: sum of 3 quarters · filed 2015-08-31 | -$17.11M 10-K · filed 2015-08-31 | |
| 2014-03-31 | $42.00K 10-Q · filed 2015-05-11 | $509.00K derived: sum of 2 quarters · filed 2015-05-11 | -$16.89M 10-Q · filed 2015-05-11 | -$16.36M derived: sum of 4 quarters · filed 2015-08-31 | |
| 2013-12-31 | $467.00K 10-Q · filed 2015-02-09 | -$16.93M 10-Q · filed 2015-02-09 | -$16.40M derived: sum of 3 quarters · filed 2015-08-31 | -$9.79M derived: sum of 4 quarters · filed 2015-08-31 | |
| 2013-09-30 | -$17.40M 10-Q · filed 2014-11-10 | -$16.87M derived: sum of 2 quarters · filed 2015-08-31 | -$10.26M derived: sum of 3 quarters · filed 2015-08-31 | -$11.94M derived: sum of 4 quarters · filed 2015-08-31 | |
| 2013-06-30 | $530.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $7.14M derived: sum of 2 quarters · filed 2015-08-31 | $5.46M derived: sum of 3 quarters · filed 2015-08-31 | -$2.13M 10-K · filed 2015-08-31 | |
| 2013-03-31 | $6.61M 10-Q · filed 2014-05-12 | $4.93M derived: sum of 2 quarters · filed 2014-05-12 | -$2.66M 10-Q · filed 2014-05-12 | $7.44M derived: sum of 4 quarters · filed 2014-08-29 | |
| 2012-12-31 | -$1.68M 10-Q · filed 2014-02-04 | -$9.27M 10-Q · filed 2014-02-04 | $834.00K derived: sum of 3 quarters · filed 2014-08-29 | $14.16M derived: sum of 4 quarters · filed 2014-08-29 | |
| 2012-09-30 | -$7.59M 10-Q · filed 2013-11-12 | $2.51M derived: sum of 2 quarters · filed 2014-08-29 | $15.84M derived: sum of 3 quarters · filed 2014-08-29 | $15.85M derived: sum of 4 quarters · filed 2014-08-29 | |
| 2012-06-30 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $23.43M derived: sum of 2 quarters · filed 2014-08-29 | $23.44M derived: sum of 3 quarters · filed 2014-08-29 | $23.42M 10-K · filed 2014-08-29 | |
| 2012-03-31 | $13.33M 10-Q · filed 2013-05-10 | $13.34M derived: sum of 2 quarters · filed 2013-05-10 | $13.32M 10-Q · filed 2013-05-10 | ||
| 2011-12-31 | $11.00K 10-Q · filed 2013-02-11 | -$7.00K 10-Q · filed 2013-02-11 | |||
| 2011-09-30 | -$18.00K 10-Q · filed 2012-11-09 | ||||
| 2011-06-30 | -$44.00K 10-K · filed 2013-08-29 | ||||
| 2010-06-30 | $97.00K 10-K · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |